Search research articles
Contact Us
Filters
Showing results (21-30 of 207) with videos related to
Page
of 21
Sort By:
Science (New York, N.Y.)
|
July 10, 2010
HIV/AIDS. Universal access in the fight against HIV/AIDS
Françoise Girard, Nathan Ford, Julio Montaner, et al.
Clinical Drug Investigation
|
January 24, 2008
Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection
Pedro Cahn, Maria Rolon, Isabel Cassetti, et al.
Journal of the International AIDS Society
|
November 15, 2014
Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity
Patricia Patterson, Eugenia Socías, Daniel Pryluka, et al.
Antiviral Chemistry & Chemotherapy
|
June 5, 2007
Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection
Mark A Wainberg, Pedro Cahn, Richard C Bethell, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
May 24, 2011
Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children
Shirin Heidari, Lynne Mofenson, Mark F Cotton, et al.
Therapeutic Advances in Infectious Disease
|
February 21, 2024
Preference for long-acting injectable for ART and PrEP among people with and without HIV: a cross-sectional study in Argentina
Sergio Sciannameo, Virginia Zalazar, Luciana Spadaccini, et al.
AIDS Care
|
January 23, 2013
Sexual risk-taking behaviour among HIV outpatients in Argentina
Richard Harding, Jorge H Eisenchlas, Rita Strauss, et al.
Journal of the International AIDS Society
|
May 25, 2017
Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
Pedro Cahn, María José Rolón, María Inés Figueroa, et al.
Medicina
|
April 6, 2007
[Occupational exposure to hepatitis C virus]
Javier José Ricart, Valeria Fink, Mercedes Cabrini, et al.
Actualizaciones En SIDA E Infectologia
|
February 2, 2023
[Retention in care and distance between home and hospital in HIV patients of Buenos Aires City]
Gabriela Alejandra Blugerman, José Antonio Valiente, Carina Cesar, et al.
Page
of 21
Search research articles
Search
Showing results (21-30 of 207) with videos related to
Sort By:
Page
of 21
Science (New York, N.Y.)
|
July 10, 2010
HIV/AIDS. Universal access in the fight against HIV/AIDS
Françoise Girard, Nathan Ford, Julio Montaner, et al.
Clinical Drug Investigation
|
January 24, 2008
Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection
Pedro Cahn, Maria Rolon, Isabel Cassetti, et al.
Journal of the International AIDS Society
|
November 15, 2014
Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity
Patricia Patterson, Eugenia Socías, Daniel Pryluka, et al.
Antiviral Chemistry & Chemotherapy
|
June 5, 2007
Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection
Mark A Wainberg, Pedro Cahn, Richard C Bethell, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
May 24, 2011
Antiretroviral drugs for preventing mother-to-child transmission of HIV: a review of potential effects on HIV-exposed but uninfected children
Shirin Heidari, Lynne Mofenson, Mark F Cotton, et al.
Therapeutic Advances in Infectious Disease
|
February 21, 2024
Preference for long-acting injectable for ART and PrEP among people with and without HIV: a cross-sectional study in Argentina
Sergio Sciannameo, Virginia Zalazar, Luciana Spadaccini, et al.
AIDS Care
|
January 23, 2013
Sexual risk-taking behaviour among HIV outpatients in Argentina
Richard Harding, Jorge H Eisenchlas, Rita Strauss, et al.
Journal of the International AIDS Society
|
May 25, 2017
Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
Pedro Cahn, María José Rolón, María Inés Figueroa, et al.
Medicina
|
April 6, 2007
[Occupational exposure to hepatitis C virus]
Javier José Ricart, Valeria Fink, Mercedes Cabrini, et al.
Actualizaciones En SIDA E Infectologia
|
February 2, 2023
[Retention in care and distance between home and hospital in HIV patients of Buenos Aires City]
Gabriela Alejandra Blugerman, José Antonio Valiente, Carina Cesar, et al.
Page
of 21